Suven Life Sciences Limited
SUVEN · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹431.76. Low-confidence estimate — limited data.
Piotroski F-score 1/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%-78.8%
- ✓Low debt (D/E < 0.5)0.03x
- ✕Positive free cash flow
- ✕Revenue growth > 10%4%
- –Earnings growing
- ✕Net margin ≥ 10%0.0%
- ✓Current ratio > 1.517.70
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 129.77
- ✕Piotroski ≥ 71/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 129.77.
Weaknesses
- •Low return on equity (-78.8%).
- •Weak Piotroski score (1/9).
Opportunities
- •Trades ~100% below our estimated fair value.
Threats
- •Rich valuation versus sector peers.
About Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neu
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.